AbbVie Inc.

ABBV

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions. Next phase2 readout (ABT-712 Extended-release): Aug 2009. Short interest: 1.1% of float.

Drug Manufacturers - GeneralCEO: Scott T. ReentsIPO: 2013Website ↗

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Catalysts

Phase 3NegativeQ1 2009ABT-712Chronic Low Back PainNCT00761150

Primary: Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS) (Double-blind baseline to 4 weeks)Enrollment:308/308Sites: 32RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2009ABT-874Moderate to Severe Plaque PsoriasisNCT00710580

Primary: Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12 (12 Weeks)Enrollment:350/350Sites: 42RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2009ABT-712 Extended-releasePainNCT00935311

Primary: Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS) (From time of first study drug administration to 12 hours following first study drug administration)Enrollment:122/122Sites: 3RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2010Leuprorelin Acetate DepotEndometriosisNCT00797225

Primary: Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain (Baseline and Weeks 4, 8, and 12)Enrollment:174/174RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2010PlaceboAlzheimer's DiseaseNCT00948909

Primary: ADAS-Cog - Alzheimer's Disease Assessment Scale Cognition portion (Measurements up through 12 weeks.)Enrollment:274/274Sites: 29RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2011ABT-869Advanced Renal Cell CarcinomaNCT00486538

Primary: Objective Response Rate (From randomization until patient death or alive at 2 years)Enrollment:53/53Sites: 13NON_RANDOMIZED, TREATMENT

Phase 2Q2 2011ABT-869Advanced Hepatocellular CarcinomaNCT00517920

Primary: Progression-Free Rate (Week 16)Enrollment:44/44Sites: 6NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2011AdalimumabPeripheral SpondyloarthritisNCT01064856

Primary: Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12 (Week 12)Enrollment:165/165RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ4 2011ABT-450Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C VirusNCT01306617

Primary: Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) From Week 4 Through Week 12 (Week 4 through Week 12)Enrollment:50/50Sites: 11NON_RANDOMIZED, TREATMENT

Phase 2Q2 2012ABT-869Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the RectumNCT00707889

Primary: Progression-free survival (Radiographic evaluation every 2 months, clinial evaluation every 2 weeks)Enrollment:159/159Sites: 46RANDOMIZED, TREATMENT

Phase 2Q2 2013ABT-888Ovarian CancerNCT01113957

Primary: Objective response rate between the two treatment arms (ABT-888 + temozolomide versus the PLD) will be based on tumor measurements and CA-125 levels. (Screening to survival follow-up (every 3 months for 3 years))Enrollment:168/168Sites: 32RANDOMIZED, TREATMENT

Phase 2Q3 2013NavitoclaxChronic Lymphocytic LeukemiaNCT01557777

Primary: Safety: Adverse Events - The number of participants with adverse events will be reported as a measure of Safety. (Adverse events occuring through the Final Visit (up to Week 52) will be reported)Enrollment:17/17Sites: 15NON_RANDOMIZED, BASIC_SCIENCE

Phase 2Q4 2013New formulation adalimumabRheumatoid ArthritisNCT01752855

Primary: Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 36 and 48 (Baseline (Study NCT01712178 Week 0 Visit), Weeks 36 and 48)Enrollment:88/88Sites: 20NA, TREATMENT

Phase 2PositiveQ2 2014ABT-450/ritonavir, ABT-267Chronic Hepatitis C InfectionNCT01672983

Primary: Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24) (24 weeks after last dose of study drug)Enrollment:110/110RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2014ABT-450/r/ABT-267, ABT-333Chronic Hepatitis C InfectionNCT01854697

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses (12 weeks after the last actual dose of active study drug)Enrollment:311/311RANDOMIZED, TREATMENT

Phase 3ApprovedQ1 2015Levodopa-carbidopa intestinal gelAdvanced Parkinson's DiseaseNCT01960842

Primary: Average Daily Normalized "Off" Time: Change From Baseline To The Final PEG-J Visit (Baseline (end of screening period) and Final PEG-J Visit (up to week 12))Enrollment:31/31NA, TREATMENT

Phase 3PositiveQ1 2015Levodopa-Carbidopa Intestinal GelAdvanced Parkinson's DiseaseNCT01736176

Primary: Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score (Baseline and Week 12)Enrollment:39/39NA, TREATMENT

Phase 3ApprovedQ2 2016ElagolixEndometriosisNCT02143713

Phase 2PositiveQ4 2016ombitasvir/paritaprevir/ritonavir and dasabuvirChronic Hepatitis C InfectionNCT02356562

Phase 3PositiveQ4 2016ABT-493, ABT-530Chronic Hepatitis C, Hepatitis C Virus, HCVNCT02446717

Phase 3PositiveQ1 2017ABT-493/ABT-530Chronic Hepatitis C, Hepatitis C Virus, HCVNCT02604017

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Mono-infected Hepatitis C Virus Genotype 1 (HCV GT1), Direct-acting Antiviral Agent (DAA) Naïve Participants in the 12-Week Treatment Arm (12 weeks after the last actual dose of study drug)Enrollment:703/703RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2017DalbavancinEndocarditis, BacteremiaNCT03148756

Primary: Number of Participants With Clinical Response at Day 84 in the Intent-to Treat (ITT) Population (Day 84)Enrollment:2/2Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 2PositiveQ4 2017placeboAsthmaNCT02443298

Phase 3PositiveQ4 2017Placebo for AdalimumabRheumatoid ArthritisNCT02629159

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12)Enrollment:1,629/1,629Sites: 370RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2018PlaceboMetastatic Breast CancerNCT01506609

Primary: Progression-Free Survival (PFS) (Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for PFS was 34 months.)Enrollment:294/294Sites: 120RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2020PlaceboPsoriatic Arthritis (Ps A)NCT03671148

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24)Enrollment:444/444Sites: 138RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2020TemozolomideMalignant Glioma, Glioblastoma MultiformeNCT02590263

Phase 3Q4 2020PlaceboPsoriatic ArthritisNCT03675308

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24)Enrollment:964/964Sites: 256RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2021PlaceboAtopic DermatitisNCT03568318

Phase 2NegativeQ3 2021elezanumabMultiple Sclerosis (MS)NCT03737851

Phase 3PositiveQ3 2021Matching Placebo for UpadacitinibCrohn's DiseaseNCT03345836

Phase 3PositiveQ4 2021UpadacitinibCrohn's DiseaseNCT03345849

Phase 3PositiveQ4 2021AzacitidineAcute Myeloid Leukemia (AML)NCT02993523

Primary: Overall Survival (OS) (From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021))Enrollment:443/443Sites: 172RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2022AGN-151607Post-Operative Atrial FibrillationNCT03779841

Phase 3Sep 29, 2022VenetoclaxAcute Myeloid Leukemia (AML)NCT04102020

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1) (Up to 28 days (Cycle 1))Enrollment:112/112Sites: 156NON_RANDOMIZED, TREATMENT

Phase 3Q4 2022OnabotulinumtoxinAPlatysma ProminenceNCT04949399

Primary: Number of Participants With Adverse Events (Enrollment to Day 120)Enrollment:408/408Sites: 30RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2023IMGN632Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative NeoplasmNCT03386513

Primary: To assess the rate of composite CR in BPDCN patients (21-day cycle)Enrollment:179/179Sites: 28NA, TREATMENT

Phase 2Jun 13, 2024VenetoclaxRefractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic LeukemiaNCT05192889

Phase 2PositiveQ3 2024ABBV-552Alzheimer's Disease (AD)NCT05771428

Phase 3NegativeQ4 2024BOTOXEpisodic MigraineNCT05028569

Phase 2NegativeQ4 2024CVL-865SeizuresNCT04686786

Phase 3Q1 2025NavitoclaxMyelofibrosis (MF)NCT04468984

Phase 3Q2 2025AdalimumabUlcerative ColitisNCT02632175

Phase 3Q3 2025AtogepantMigraineNCT06241313

Phase 2NegativeQ3 2025BudigalimabHuman Immuno-deficiency Virus (HIV) DiseaseNCT06032546

Phase 3Sep 23, 2025UpadacitinibVitiligoNCT06118411

Phase 3Q4 2025BOTOXMasseter Muscle ProminenceNCT06387394

Phase 3Q1 2026Open-Angle GlaucomaNCT05411198

Phase 2Q2 2026TNB-383BMultiple MyelomaNCT03933735

Primary: Number of Participants with Dose-limiting toxicities (DLT) (Day 21)Enrollment:220/220Sites: 14NON_RANDOMIZED, TREATMENT

Phase 3Q2 2026Placebo for Risankizumab SCCrohn's DiseaseNCT03105102

Phase 3Q2 2026AtogepantMenstrual Migraine (MM)NCT06806293

Phase 2Q2 2026Topical SteroidDiabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)NCT04567550

Phase 2Q2 2026Mirvetuximab SoravtansineRecurrent Ovarian Cancer, Folate Receptor-Alpha PositiveNCT06365853

Phase 3Q3 2026UpadacitinibRheumatoid ArthritisNCT05814627

Primary: Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2 (Week 12)Enrollment:487/487Sites: 218RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026Telisotuzumab vedotinNon-small Cell Lung CancerNCT03539536

Phase 3Q3 2026Bimatoprost SROpen-Angle Glaucoma, Ocular HypertensionNCT03891446

Phase 2Q3 2026Mirvetuximab SoravtansineAdvanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube CancersNCT06682988

Phase 3Q3 2026Atrophic Acne ScarsNCT05995340

Phase 3Q3 2026ABBV-444Dry Eye DiseaseNCT07284381

Primary: Change from Baseline in Ocular Surface Disease Index (OSDI) Score (Baseline to Day 90)Enrollment:Target 250Sites: 20RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2026PomalidomideMultiple MyelomaNCT03539744

Phase 3Q3 2026Upadacitinib 15mg DoseAtopic DermatitisNCT06389136

Phase 2Q3 2026RanibizumabNeovascular Age-Related Macular Degeneration (n AMD)NCT04514653

Phase 3Q3 2026Mid Face Volume DeficitNCT07032597

Phase 3Q3 2026AdalimumabJuvenile Psoriatic ArthritisNCT06100744

Phase 3Q4 2026Aflibercept (EYLEA®)AMD, n AMD, Wet Age-related Macular DegenerationNCT05407636

Phase 2Q4 2026ABBV-932Generalized Anxiety Disorder (GAD)NCT06846320

Phase 2Q4 2026Mirvetuximab soravtansineHigh Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube CancerNCT05456685

Phase 2Q4 2026MEDI0618MigraineNCT06602479

Phase 3Q4 2026LutikizumabHidradenitis SuppurativaNCT06468228

Phase 2Q4 2026ABBV-400Unresectable Metastatic Colorectal CancerNCT06107413

Phase 3Q4 2026Ranibizumab (LUCENTIS®)AMD, n AMD, Wet Age-related Macular DegenerationNCT04704921

Primary: Mean change from baseline in Best Corrected Visual Acuity (BCVA) (At Week 54)Enrollment:671/671Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2026EluxadolineIrritable Bowel SyndromeNCT03339128

Phase 3Q1 2027PlaceboAtopic DermatitisNCT06701331

Phase 2Q1 2027LutikizumabRheumatoid ArthritisNCT06972446

Phase 2Q1 2027LutikizumabHidradenitis Suppurativa, Atopic DermatitisNCT06524635

Phase 2Q1 2027AzacitidineAcute Myeloid LeukemiaNCT04086264

Phase 2Q1 2027LivmoniplimabUrothelial CarcinomaNCT06632951

Phase 3Q1 2027CariprazineDepression, Bipolar I DisorderNCT04777357

Phase 3Q1 2027Risankizumab SCCrohn's DiseaseNCT06063967

Phase 3Q1 2027UpadacitinibSystemic Lupus ErythematosusNCT05843643

Phase 3Q2 2027Mirvetuximab soravtansine plus BevacizumabOvarian Cancer, Peritoneal Cancer, Fallopian Tube CancerNCT05445778

Phase 2Q2 2027ABBV-932Bipolar I or II DisorderNCT07220460

Phase 3Q2 2027UbrogepantMigraineNCT05125302

Phase 2Q2 2027LutikizumabAtopic DermatitisNCT06718101

Phase 2Q2 2027CarfilzomibMultiple MyelomaNCT02899052

Phase 3Q2 2027UbrogepantMigraineNCT06417775

Phase 3Q2 2027UpadacitinibCrohn's DiseaseNCT06332534

Primary: Percentage of participants who achieved clinical response per the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12, with clinical remission per the PCDAI at Week 64 (At Week 64)Enrollment:Target 110Sites: 83RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2027Upadacitinib (ABT-494)Ulcerative Colitis (UC)NCT03006068

Phase 3Q3 2027VenetoclaxMyelodysplastic Syndrome (MDS)NCT04401748

Phase 3Q3 2027VenetoclaxChronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple MyelomaNCT03844048

Phase 3Q3 2027Telisotuzumab AdizutecanMetastatic Colorectal CancerNCT06614192

Phase 3Q3 2027RisankizumabUlcerative ColitisNCT06880744

Phase 3Q3 2027UpadacitinibCrohn's DiseaseNCT03345823

Phase 2Q3 2027LutikizumabUlcerative ColitisNCT06257875

Phase 2Q3 2027IcalcaprantMajor Depressive DisorderNCT07276997

Phase 2Q4 2027Telisotuzumab AdizutecanNon Small Cell Lung CarcinomaNCT06772623

Primary: Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan (Up to Approximately 84 Days)Enrollment:Target 252Sites: 55RANDOMIZED, TREATMENT

Phase 2Q4 2027IcalcaprantBipolar I Disorder, Bipolar II DisorderNCT06696755

Phase 2Q4 2027LutikizumabPsoriatic ArthritisNCT06865105

Phase 3Q4 2027EtentamigMultiple MyelomaNCT06158841

Phase 2Q4 2027LutikizumabHidradenitis SuppurativaNCT05139602

Phase 2Q1 2028IMGN151Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube CancerNCT07024784

Phase 3Q1 2028UbrogepantMigraineNCT05127954

Phase 2Q1 2028ABBV-383 (Etentamig)Immunoglobulin Light Chain (AL) AmyloidosisNCT06158854

Phase 2Q1 2028Telisotuzumab VedotinNon-Small Cell Lung CancerNCT06568939

Phase 2Q1 2028EmraclidineSchizophreniaNCT07145918

Primary: Number of Participants with Adverse Events (AEs) (Up to approximately 74 days)Enrollment:Target 268Sites: 7RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2028RisankizumabCrohn's Disease (CD)NCT04524611

Phase 3Q1 2028UpadacitinibHidradenitis SuppurativaNCT05889182

Phase 2Q1 2028Telisotuzumab AdizutecanMetastatic Colorectal CancerNCT06820463

Phase 3Q1 2028AtogepantEpisodic MigraineNCT05711394

Primary: Change from Baseline in Mean Monthly Migraine Days (Baseline (Week 0) through Week 12)Enrollment:Target 450Sites: 98RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2028VenetoclaxChronic Lymphocytic LeukemiaNCT06428019

Phase 3Q2 2028RisankizumabPsoriasisNCT04862286

Phase 3Q2 2028Surabgene LomparvovecDiabetic RetinopathyNCT07592273

Phase 2Q3 2028VenetoclaxWaldenstrom Macroglobulinemia, Lymphoplasmacytic LymphomaNCT07387471

Phase 3Q3 2028UpadacitinibUlcerative ColitisNCT05782907

Phase 3Q3 2028UpadacitinibTakayasu Arteritis (TAK)NCT04161898

Phase 3Q3 2028risankizumabUlcerative Colitis (UC)NCT03398135

Phase 2Q3 2028Telisotuzumab AdizutecanColorectal CancerNCT06464692

Phase 2Q3 2028AGN-151607-DPVentral HerniaNCT07226791

Phase 2Q4 2028AGN-151607-DPUpper Limb Essential TremorNCT07673107

Phase 3Q4 2028Primary Open Angle GlaucomaNCT06822738

Phase 2Q4 2028Neovascular Age-related Macular Degeneration, Wet Macular DegenerationNCT03999801

Phase 3Q4 2028Telisotuzumab VedotinNon Small Cell Lung CancerNCT04928846

Primary: Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR) (Up to approximately 39 months)Enrollment:Target 698Sites: 316RANDOMIZED, TREATMENT

Phase 2Q1 2029Mirvetuximab SoravtansineOvarian CancerNCT07059845

Phase 3Q1 2029ElagolixEndometriosisNCT04333576

Phase 2Q2 2029AGN-193408 SROpen-angle Glaucoma, Ocular HypertensionNCT04499248

Phase 3Q2 2029RisankizumabCrohn's DiseaseNCT05995353

Phase 2Q2 2029ABBV-706Small Cell Lung CancerNCT07155174

Phase 3Q2 2029Telisotuzumab adizutecanColorectal CancerNCT07525206

Phase 3Q2 2029UpadacitinibJuvenile Idiopathic ArthritisNCT05609630

Phase 3Q3 2029Mid Face Volume DeficitNCT06734351

Phase 2Q3 2029ABBV-142Idiopathic Pulmonary FibrosisNCT07230288

Phase 2Q4 2029ABBV-6628Geographic Atrophy, Age-Related Macular DegenerationNCT07160179

Phase 2Q4 2029Telisotuzumab AdizutecanColorectal CancerNCT07023289

Phase 3Q4 2029Acne ScarsNCT07207369

Phase 2Jan 15, 2030Loncastuximab Tesirine and EpcoritamabAggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3BNCT07197307

Phase 2Q1 2030RisankizumabCrohn's DiseaseNCT06548542

Phase 2Q1 2030CarboplatinEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerNCT06890338

Phase 2Q2 2030ABBV-1758Alzheimer's DiseaseNCT07599670

Phase 3Q2 2030UpadacitinibAlopecia AreataNCT06012240

Phase 3Q3 2030UpadacitinibAtopic DermatitisNCT06461897

Phase 3Q3 2030LivmoniplimabHepatocellular CarcinomaNCT06109272

Primary: Stage 1: Best Overall Response (BOR) per Investigator (Through Study Completion, Up to Approximately 56 Months)Enrollment:Target 660Sites: 37RANDOMIZED, TREATMENT

Phase 3Q3 2030ABBV-706Small Cell Lung CancerNCT07365241

Phase 3Q3 2030Telisotuzumab AdizutecanNon-Small Cell Lung CancerNCT07155187

Phase 2Q4 2030Telisotuzumab AdizutecanLocally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal AdenocarcinomaNCT06628310

Phase 2Q4 2030ABBV-453Multiple MyelomaNCT06953960

Phase 2Q4 2030VenetoclaxChronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)NCT02966756

Phase 2Q4 2030Telisotuzumab AdizutecanSolid Tumors Harboring MET AmplificationNCT07196644

Phase 3Q1 2031Breast ReconstructionNCT06575192

Phase 3Q1 2031AtogepantChronic MigraineNCT06810505

Phase 2Q2 2031DexamethasoneMultiple MyelomaNCT03314181

Phase 2Q2 2031Standard of CareDiabetic Retinopathy, DRNCT05296447

Phase 3Q2 2031Telisotuzumab adizutecanMetastatic Pancreatic Ductal Adenocarcinoma, PDACNCT07490301

Phase 2Q4 2031RisankizumabCrohn's Disease, Ulcerative ColitisNCT07697456

Phase 3Q4 2031LivmoniplimabNon-Small Cell Lung CancerNCT06236438

Primary: Stage 1: Best Overall Response (BOR) of Complete Response (CR)/Partial Response (PR) (Up to 21 Months)Enrollment:Target 840Sites: 61RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2031Standard of CareNon-Squamous Non-Small Cell Lung CancerNCT07005102

Phase 3Q2 2032Pivekimab SunirineAcute Myeloid LeukemiaNCT07581002

Phase 2Q4 2032EpcoritamabNon-Hodgkin LymphomaNCT05283720

Phase 3Q4 203225mg EluxadolineIrritable Bowel SyndromeNCT04880876

Phase 3Q1 2033EtentamigRelapsed or Refractory Multiple MyelomaNCT07728188

Phase 3Q1 2033Surabgene Lomparvovec (ABBV-RGX-314)Neovascular Age-related Macular DegenerationNCT07007065

Phase 3Q3 2034RisankizumabUlcerative ColitisNCT07071519

Phase 2Q1 2036EtentamigMultiple MyelomaNCT06892522

Phase 3Q1 2042EtentamigMultiple MyelomaNCT07095452

Recent News & Research

bioRxiv

Branch-resolved IFN/STING-linked lesion-state architecture in psoriasis: multi-cohort derivation, held-out bulk replication and single-cell context analysis

# Investment Summary: AbbVie Psoriasis Research **Clinical/Commercial Relevance:** This preprint identifies distinct IFN/STING-pathway activation states in psoriatic lesions through multi-cohort analysis, potentially enabling patient stratification for targeted immunotherapy response. If validated, these biomarkers could improve outcomes for AbbVie's psoriasis portfolio (risankizumab, upadacitinib) by identifying responder populations or informing combination therapy strategies, though the work remains unpublished and requires clinical translation. **Investment Implications:** The findings could support label expansions or companion diagnostic development but represent early mechanistic research; clinical utility depends on prospective validation and integration into existing treatment algorithms, which typically requires 2-3+ years. Monitor for peer-reviewed publication and whether AbbVie pursues biomarker-driven development pathways in this indication.

Jul 22, 2026

bioRxiv

Azacitidine Response in Myelodysplastic Syndromes is Marked by NK-like CD8 T-Cell Expansion and CXCL12+ Reticular Cell Remodeling

# Investment Summary: ABBV Azacitidine Response Mechanism **Clinical Finding:** This preprint identifies that azacitidine's efficacy in myelodysplastic syndromes (MDS) correlates with expansion of NK-like CD8 T cells and remodeling of bone marrow stromal cells (CXCL12+ reticular cells), suggesting an immunological mechanism beyond direct DNA methyltransferase inhibition. **Commercial Implications:** Understanding azacitidine's immunological mechanism could enable patient stratification biomarkers to identify responders upfront, potentially improve response rates through combination strategies (e.g., with immune checkpoint inhibitors), and extend the addressable MDS market—relevant to ABBV's Onureg franchise, which generated ~$650M in 2024 revenue. **Investor Note:** As a preprint, these findings require peer-review

Jul 8, 2026

bioRxiv

Joint tissue explant model using psoriatic arthritis synovial fluid as a tool to capture patient-specific responses to treatments

# Investment Summary: ABBV Psoriatic Arthritis Research **Clinical/Commercial Relevance:** This bioRxiv preprint describes a patient-derived ex vivo model using psoriatic arthritis (PsA) synovial fluid to test treatment responses at the individual level, potentially enabling more precise efficacy prediction before clinical trials. For AbbVie, which markets Rinvoq (upadacitinib) and other immunology assets for PsA, this approach could improve patient stratification, reduce clinical trial failure risk, and support personalized medicine claims—though the early-stage nature (preprint, not peer-reviewed) and lack of commercial validation data limit immediate implications. Investors should monitor whether this or similar biomarker-driven models gain adoption in ABBV's pipeline development, as they could enhance R&D efficiency in competitive inflammatory disease markets. --- **Key Caveats:**

Jul 8, 2026

bioRxiv

Patient-Derived Organoids Functionally Stratify Epithelial Ovarian Cancer into Clinically Relevant Chemotherapy Response Phenotypes

# Investment Summary: AbbVie Relevance **Note:** This appears to be a preprint (bioRxiv) with a future date, so treat conclusions as preliminary. **Summary:** Researchers demonstrated that patient-derived ovarian cancer organoids can predict individual chemotherapy response patterns, potentially enabling personalized treatment selection and reducing exposure to ineffective standard regimens. For AbbVie, this advance could support companion diagnostic development for its oncology pipeline or validate existing ovarian cancer assets (such as rucaparib) by identifying patient populations most likely to benefit. The clinical value hinges on whether organoid-based stratification improves outcomes or reduces treatment burden compared to current empirical approaches, with commercial implications depending on adoption rates and payor reimbursement for the diagnostic. **Key consideration for investors:** Monitor whether this platform achieves clinical validation in prospective trials, as organoid-based diagnostics face adoption hurdles despite theoretical

Jul 7, 2026

bioRxiv

Tumor-selective Mcl1 degradation by AUTAC uncouples antitumor efficacy from cardiotoxicity

# Investment Summary: AbbVie Mcl-1 AUTAC Program **Clinical/Commercial Significance:** This research demonstrates a potential solution to a major clinical liability in Mcl-1-targeted cancer therapies—cardiotoxicity—through AUTAC (Autophagy-TargeTing Chimera) technology that selectively degrades Mcl-1 in tumor cells while sparing cardiac tissue. If validated in preclinical models and clinical development, this approach could expand the therapeutic window for Mcl-1 inhibitors, particularly in hematologic malignancies where Mcl-1 dependency is common. For AbbVie, this represents intellectual property development around a selective degradation mechanism that could differentiate future oncology candidates and potentially rescue programs limited by cardiac safety concerns. **Investor Relevance:** The cardiac toxicity mitigation is material because it addresses a key regulatory and

Jun 24, 2026

AbbVie Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research